Literature DB >> 19501454

Current technique of open intrafascial nerve-sparing retropubic prostatectomy.

Lars Budäus1, Hendrik Isbarn, Thorsten Schlomm, Hans Heinzer, Alexander Haese, Thomas Steuber, Georg Salomon, Hartwig Huland, Markus Graefen.   

Abstract

BACKGROUND: Open nerve-sparing retropubic prostatectomy (nsRP) is still the most common surgical approach for the treatment of localised prostate cancer. Even though the principles of the technique and its oncological efficacy have often been published, ongoing refinements allow further improvements in functional outcome and morbidity.
OBJECTIVE: To describe our current technique of open nsRP with data addressing urinary continence, potency, cancer control rates, and perioperative morbidity. DESIGN, SETTING, AND PARTICIPANTS: Our analyses relied on 1150 patients who were treated with nsRP in the Martini-Clinic by two high-volume surgeons from April 2005 to December 2007. SURGICAL PROCEDURE: Key elements are a selective ligation of the dorsal vein complex and early release of the neurovascular bundles using a high anterior tension- and energy-free intrafascial technique. During dissection of the urethra, its posterior insertion at Denonvilliers' fascia (DF) is preserved. DF is left in situ, and it is selectively opened above the seminal vesicles (SV). The SV are completely removed inside DF, and five muscle-sparing interrupted sutures are used for anastomosis. MEASUREMENTS: Functional and oncological outcome data were prospectively assessed using validated questionnaires. Moreover, intra- and perioperative morbidity were evaluated. RESULTS AND LIMITATIONS: Age and extent of nerve-sparing approach influenced urinary continence and potency. Complete urinary continence 1 yr after nsRP was found in 97.4% (men <60 yr) to 84.1% (men >70 yr) of patients. In preoperative potent men, erections sufficient for intercourse were reported between 84-92% and 58.3-70% of patients following bilateral and unilateral nerve sparing, respectively. Median blood loss was 580 ml (range: 130-1800 ml), and the transfusion rate was 4.3%. Median operative time was 165 min (range: 85-210 min). In organ-confined cancers, recurrence-free survival and cancer-specific-survival 10 yr after retropubic prostatectomy were 87% and 98.3%, respectively.
CONCLUSIONS: Open intrafascial nsRP combines excellent long-term cancer control rates with superior functional outcome and a low morbidity.

Entities:  

Mesh:

Year:  2009        PMID: 19501454     DOI: 10.1016/j.eururo.2009.05.044

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  22 in total

1.  Intraoperative Frozen Section of the Prostate Reduces the Risk of Positive Margin Whilst Ensuring Nerve Sparing in Patients with Intermediate and High-Risk Prostate Cancer Undergoing Robotic Radical Prostatectomy: First Reported UK Series.

Authors:  Nikhil Vasdev; Samita Agarwal; Bhavan P Rai; Arany Soosainathan; Gregory Shaw; Sebastian Chang; Venkat Prasad; Gowrie Mohan-S; James M Adshead
Journal:  Curr Urol       Date:  2016-05-20

2.  Tumor characteristics, oncological and functional outcomes after radical prostatectomy in very young men ≤ 45 years of age.

Authors:  Derya Tilki; Valentin Maurer; Raisa S Pompe; Felix K Chun; Felix Preisser; Alexander Haese; Markus Graefen; Hartwig Huland; Philipp Mandel
Journal:  World J Urol       Date:  2019-04-02       Impact factor: 4.226

3.  No impact of blood transfusion on oncological outcome after radical prostatectomy in patients with prostate cancer.

Authors:  K Boehm; B Beyer; P Tennstedt; J Schiffmann; L Budaeus; A Haese; M Graefen; T Schlomm; H Heinzer; G Salomon
Journal:  World J Urol       Date:  2014-07-03       Impact factor: 4.226

4.  Recovery of urinary function after radical prostatectomy: predictors of urinary function on preoperative prostate magnetic resonance imaging.

Authors:  Christian von Bodman; Kazuhito Matsushita; Caroline Savage; Mika P Matikainen; James A Eastham; Peter T Scardino; Farhang Rabbani; Oguz Akin; Jaspreet S Sandhu
Journal:  J Urol       Date:  2012-01-20       Impact factor: 7.450

5.  Additional elastography-targeted biopsy improves the agreement between biopsy Gleason grade and Gleason grade at radical prostatectomy.

Authors:  Katharina Boehm; Pierre Tennstedt; Burkhard Beyer; Jonas Schiffmann; Ann Beckmann; Uwe Michl; Dirk Beyersdorff; Lars Budäus; Markus Graefen; Pierre I Karakiewicz; Georg Salomon
Journal:  World J Urol       Date:  2015-10-19       Impact factor: 4.226

6.  Safe-R: a novel score, accounting for oncological safe nerve-sparing at radical prostatectomy for localized prostate cancer.

Authors:  Andreas Becker; Carolina Coelius; Meike Adam; Pierre Tennstedt; Luis Kluth; Thomas Steuber; Hans Heinzer; Markus Graefen; Thorsten Schlomm; Uwe Michl
Journal:  World J Urol       Date:  2014-03-26       Impact factor: 4.226

7.  Impact of surgeon-defined capsular incision during radical prostatectomy on biochemical recurrence rates.

Authors:  Philipp Mandel; Su J Oh; Christoph Hagner; Pierre Tennstedt; Maximilian C Kriegmair; Hartwig Huland; Markus Graefen; Derya Tilki
Journal:  World J Urol       Date:  2016-03-22       Impact factor: 4.226

8.  Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment.

Authors:  Philipp Mandel; Clemens Rosenbaum; Raisa S Pompe; Thomas Steuber; Georg Salomon; Felix K Chun; Markus Graefen; Hartwig Huland; Derya Tilki
Journal:  World J Urol       Date:  2017-08-21       Impact factor: 4.226

9.  Myth busting patient's pain: comparing robotic-assisted verses open radical prostatectomies.

Authors:  Benjamin Condon; Dominic Bagguley; Nathan Lawrentschuk
Journal:  Gland Surg       Date:  2020-04

10.  Results of radical prostatectomy in newly diagnosed prostate cancer: long-term survival rates in locally advanced and high-risk cancers.

Authors:  Hendrik Isbarn; Hartwig Huland; Markus Graefen
Journal:  Dtsch Arztebl Int       Date:  2013-07-22       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.